Equipping with knowledge to improve patient-physician communication and understanding the disease.
Chronic lymphocytic leukemia (CLL) is a form of cancer, a disease in which cells grow out of control. CLL originates in the bone marrow, where cells form blood. The B lymphocytes, a type of white blood cell, are not able to fully mature into healthy cells that effectively fight infection. These leukemia cells may look somewhat normal under a microscope, but they reproduce too rapidly, survive longer than normal cells and crowd out healthy white blood cells. Eventually, the cancerous cells spill into the bloodstream, though it may be years before symptoms arise.
Each year, about 21,000 people are diagnosed with CLL. There are two types of the disease.
Other classifications of the extent of disease include the presence of enlarged lymph nodes, enlargement of the spleen, red cell counts and the presence of fever, chills and/or weight loss.
CLL is most common in older adults and rare in people under 40. The average risk of developing the disease is about 1 in 175, though men are at slightly higher risk than women. About 4,500 people die from CLL per year.
Although CLL is the most common form of leukemia in adults, it shares some features with these types of rare leukemia.
Patient-Centered Care
Patients can work with their doctors to help understand their cancer prognosis, treatment benefits and harms, the cost of care, and psychological support options. Be sure to ask the following questions:
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).
Read More
CLL and Its Treatment Can Heighten Patients’ Risk of Infections
November 8th 2023Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.
Read More